INSMED INC Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
INSMED INC (INSM) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $12.76 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-02-19
- INSMED INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $11.03M, a 230.37% increase year-over-year.
- INSMED INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $1.73M.
- INSMED INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-06-30 was $0.00.
- INSMED INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- INSMED INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $12.76M, a 41.88% increase from fiscal 2024.
- INSMED INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $8.99M, a 68.79% increase from fiscal 2023.
- INSMED INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $5.33M, a 843.19% increase from fiscal 2022.
- INSMED INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $565.00K, a 95.64% decline from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | $11.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $12.76M derived: sum of 2 quarters · filed 2026-02-19 | $12.76M derived: sum of 3 quarters · filed 2026-02-19 | $12.76M 10-K · filed 2026-02-19 | ||
| 2025-09-30 | $1.73M 10-Q · filed 2025-10-30 | $1.73M derived: sum of 2 quarters · filed 2025-10-30 | $1.73M 10-Q · filed 2025-10-30 | $5.07M derived: sum of 4 quarters · filed 2026-02-19 | ||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $3.34M derived: sum of 3 quarters · filed 2026-02-19 | $3.34M derived: sum of 4 quarters · filed 2026-02-19 | ||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $3.34M derived: sum of 2 quarters · filed 2026-02-19 | $3.34M derived: sum of 3 quarters · filed 2026-02-19 | $3.34M derived: sum of 4 quarters · filed 2026-02-19 | ||
| 2024-12-31 | $3.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $3.34M derived: sum of 2 quarters · filed 2026-02-19 | $3.34M derived: sum of 3 quarters · filed 2026-02-19 | $8.99M 10-K · filed 2026-02-19 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-10-30 | $0.00 derived: sum of 2 quarters · filed 2025-10-30 | $5.66M 10-Q · filed 2025-10-30 | $6.01M derived: sum of 4 quarters · filed 2025-10-30 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | $5.66M 10-Q · filed 2025-08-07 | $6.01M derived: sum of 3 quarters · filed 2025-08-07 | $9.10M derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-03-31 | $5.66M 10-Q · filed 2025-05-08 | $6.01M derived: sum of 2 quarters · filed 2025-05-08 | $9.10M derived: sum of 3 quarters · filed 2025-05-08 | $9.23M derived: sum of 4 quarters · filed 2025-05-08 | ||
| 2023-12-31 | $359.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $3.45M derived: sum of 2 quarters · filed 2025-02-20 | $3.58M derived: sum of 3 quarters · filed 2025-02-20 | $5.33M 10-K · filed 2025-02-20 | ||
| 2023-09-30 | $3.09M 10-Q · filed 2024-10-31 | $3.22M derived: sum of 2 quarters · filed 2024-10-31 | $4.97M 10-Q · filed 2024-10-31 | $4.97M derived: sum of 4 quarters · filed 2024-10-31 | ||
| 2023-06-30 | $130.00K 10-Q · filed 2024-08-08 | $1.88M 10-Q · filed 2024-08-08 | $1.88M derived: sum of 3 quarters · filed 2024-08-08 | $1.94M derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | $1.75M 10-Q · filed 2024-05-09 | $1.75M derived: sum of 2 quarters · filed 2024-05-09 | $1.81M derived: sum of 3 quarters · filed 2024-05-09 | $1.98M derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $58.00K derived: sum of 2 quarters · filed 2024-02-22 | $224.00K derived: sum of 3 quarters · filed 2024-02-22 | $565.00K 10-K · filed 2024-02-22 | ||
| 2022-09-30 | $58.00K 10-Q · filed 2023-10-26 | $224.00K derived: sum of 2 quarters · filed 2023-10-26 | $565.00K 10-Q · filed 2023-10-26 | $3.96M derived: sum of 4 quarters · filed 2023-10-26 | ||
| 2022-06-30 | $166.00K 10-Q · filed 2023-08-03 | $507.00K 10-Q · filed 2023-08-03 | $3.90M derived: sum of 3 quarters · filed 2023-08-03 | $4.81M derived: sum of 4 quarters · filed 2023-08-03 | ||
| 2022-03-31 | $341.00K 10-Q · filed 2023-05-04 | $3.73M derived: sum of 2 quarters · filed 2023-05-04 | $4.65M derived: sum of 3 quarters · filed 2023-05-04 | $6.75M derived: sum of 4 quarters · filed 2023-05-04 | ||
| 2021-12-31 | $3.39M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $4.31M derived: sum of 2 quarters · filed 2023-02-23 | $6.41M derived: sum of 3 quarters · filed 2023-02-23 | $12.95M 10-K · filed 2023-02-23 | ||
| 2021-09-30 | $914.00K 10-Q · filed 2022-10-27 | $3.01M derived: sum of 2 quarters · filed 2022-10-27 | $9.55M 10-Q · filed 2022-10-27 | $10.04M derived: sum of 4 quarters · filed 2022-10-27 | ||
| 2021-06-30 | $2.10M 10-Q · filed 2022-08-04 | $8.64M 10-Q · filed 2022-08-04 | $9.13M derived: sum of 3 quarters · filed 2022-08-04 | $9.64M derived: sum of 4 quarters · filed 2022-08-04 | ||
| 2021-03-31 | $6.54M 10-Q · filed 2022-05-05 | $7.03M derived: sum of 2 quarters · filed 2022-05-05 | $7.54M derived: sum of 3 quarters · filed 2022-05-05 | $7.72M derived: sum of 4 quarters · filed 2022-05-05 | ||
| 2020-12-31 | $487.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $1.00M derived: sum of 2 quarters · filed 2022-02-17 | $1.18M derived: sum of 3 quarters · filed 2022-02-17 | $1.21M 10-K · filed 2022-02-17 | ||
| 2020-09-30 | $513.00K 10-Q · filed 2021-10-28 | $696.00K derived: sum of 2 quarters · filed 2021-10-28 | $718.00K 10-Q · filed 2021-10-28 | $765.00K derived: sum of 4 quarters · filed 2021-10-28 | ||
| 2020-06-30 | $183.00K 10-Q · filed 2021-08-05 | $205.00K 10-Q · filed 2021-08-05 | $252.00K derived: sum of 3 quarters · filed 2021-08-05 | $252.00K derived: sum of 4 quarters · filed 2021-08-05 | ||
| 2020-03-31 | $22.00K 10-Q · filed 2021-05-06 | $69.00K derived: sum of 2 quarters · filed 2021-05-06 | $69.00K derived: sum of 3 quarters · filed 2021-05-06 | $69.00K derived: sum of 4 quarters · filed 2021-05-06 | ||
| 2019-12-31 | $47.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $47.00K derived: sum of 2 quarters · filed 2021-02-25 | $47.00K derived: sum of 3 quarters · filed 2021-02-25 | $47.44M 10-K · filed 2021-02-25 | ||
| 2019-09-30 | $0.00 10-Q · filed 2020-10-29 | $0.00 derived: sum of 2 quarters · filed 2020-10-29 | $47.39M 10-Q · filed 2020-10-29 | $0.00 10-Q · filed 2019-10-30 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-06 | $47.40M 10-Q · filed 2020-08-06 | $0.00 10-Q · filed 2019-08-01 | |||
| 2019-03-31 | $47.40M 10-Q · filed 2020-04-30 | |||||
| 2018-09-30 | -$7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $47.39M 10-Q · filed 2019-10-30 | ||||
| 2018-06-30 | $47.40M 10-Q · filed 2019-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |